TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01476748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaproStop
Description: One of the subject's trocars will be randomized to be used with a LaproStop device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaproStop
Description: One of the subject's trocars will be randomized to be used with a LaproStop device.
Study: NCT00000134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foscarnet
Description: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
Study: NCT02726152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoloops for closure of the appendiceal stump
Description: Application of endoloops to the appendiceal stump
Study: NCT00000134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscarnet
Description: intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
Study: NCT01465035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV and MVA-NP+M1
Description: 1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo and seasonal influenza vaccine TIV
Description: Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
Study: NCT02062515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Icotinib is administered orally 125 mg three times per day continuously for four weeks
Study: NCT00788060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: 5mg per day, continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib (Sutent)
Description: 37.5 mg per day, 14 days on, 7 day break
Study: NCT01038505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Myfortic and Sirolimus
Description: Immunosuppressive drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus, Myfortic and Sirolimus
Description: Immunosuppressive drugs
Study: NCT01476748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaproStop
Description: One of the subject's trocars will be randomized to be used with a LaproStop device.
Study: NCT01454479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and ixempra
Description: Ixabepilone 40 mg/m2 Lapatinib 250 mg
Study: NCT03129204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAF-T
Description: The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
Study: NCT02993913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmiparib
Description: Simmiparib Tablets, oral administration
Study: NCT03116373

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mandible fixation
Description: Intubation device will be fixed on mandible

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mandible fixation
Description: Intubation device will be fixed on mandible

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maxilla fixation
Description: Intubation device will be fixed on maxilla

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maxilla fixation
Description: Intubation device will be fixed on maxilla
Study: NCT00099008

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genistein
Description: oral Genistein twice daily on days 1-84
Study: NCT03520309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Treatment of all dental restorations of the children according to the diagnosis criteria

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Treatment of all dental restorations of the children according to the diagnosis criteria
Study: NCT00099008

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral Placebo twice daily on days 1-84
Study: NCT00653120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: ER capsules, 160 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inderal-LA
Description: ER capsules, 160 mg, single-dose
Study: NCT03591731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg every 6 weeks
Study: NCT03851640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-1119
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT02521974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SABIN monovalent OPV2
Description: SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
Study: NCT04666974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT
Description: Online CBT modules will be completed weekly with content mirroring in-person CBT for their diagnosis. Homework will be submitted weekly through the OPTT platform which will be reviewed by a trained professional who will provide personalized feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT
Description: Online CBT modules will be completed weekly with content mirroring in-person CBT for their diagnosis. Homework will be submitted weekly through the OPTT platform which will be reviewed by a trained professional who will provide personalized feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person CBT
Description: Participants will be assigned to in-person CBT that will mirror the content and homework covered in the iCBT group. It will be delivered by professionals and attended weekly.
Study: NCT00643942

Intervention type: OTHER
Intervention: No intervention required
Study: NCT02188719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF
Study: NCT01643057

Intervention type: DEVICE
Intervention: Stochastic Resonance Mattress
Description: The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
Study: NCT04494685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention group (Robotic rehabilitation)
Description: Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland). The training protocol has a progression of the board inclination up to 90º associated with flexion/extension movements of the knees and hips, with time evolution of up to 40 minutes. Such equipment is associated with electrostimulation of the quadriceps, hamstrings, sural triceps and anterior tibialis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group (Conventional physiotherapy)
Description: Knee and hip flexion and extension movements, hip adduction, and abduction, respecting the articular physiology of each joint. Weight transfer will also be performed in the sitting and standing position, mini squat, and gait training. All exercises will have a total of 10 repetitions in three sets. In the end, stretching of the upper and lower limbs will be performed.
Study: NCT02188719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF
Study: NCT01252589

Intervention type: OTHER
Intervention: HRQOL questionnaire
Study: NCT03440866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of drugs concomitantly.
Description: Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.
Study: NCT04416243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recumbent Stepping, High-Intensity Interval Training
Description: The intervention will involve 12 weeks of supervised, progressive (i.e., intensity increases after midpoint testing based on reassessment of aerobic fitness) HIIT sessions two to three times per week. HIIT exercise sessions will be manualized and led by exercise leaders. Secondary outcomes testing will occur at baseline (week 0), midpoint (following week 6 of training), and post-intervention (following week 12 of training).~The individual HIIT sessions will involve 10 cycles of 60s intervals at the wattage associated with 90% VO2peak followed by 60s of active recovery intervals at 15 watts, totaling 20 min in length. All exercise sessions will begin and end with a 5-minute warm-up and cool-down, respectively. Required power output for each interval of the exercise session will be individualized and completely automated. VO2peak from baseline and midpoint testing will be used to determine exercise intensity for weeks 1-6 and weeks 7-12, respectively.
Study: NCT02228538

Intervention type: DEVICE
Intervention: Total knee arthroplasty patients
Description: ConforMIS iTotal (CR) knee implant system \& off-the-shelf standard knee implant system from various manufacturers
Study: NCT02188719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
Study: NCT04446312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowel Prep
Description: Orally ingested liquid bowel preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Prep
Description: Orally ingested liquid bowel preparation
Study: NCT01576783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
Description: 200 mg DHA+ 200 mg AA per day for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg corn oil per day for 6 months
Study: NCT00670930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab at a dose of 0.016mg/kg/IU/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00200967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol
Description: 50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol
Description: 50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone HFA
Description: 240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone HFA
Description: 240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
Study: NCT01950728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential current
Description: Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 100 Hz.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aussie Current
Description: Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 100 Hz.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 100 Hz.
Study: NCT01327235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endostar
Description: intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
Study: NCT01444430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort pMDI
Description: Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide pMDI
Description: Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
Study: NCT01682356

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: double-blind placebo-controlled cross-over study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Description: double-blind placebo-controlled cross-over study
Study: NCT02267434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose AFFITOPE® PD03A + Adjuvant
Description: s.c. injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose AFFITOPE® PD03A + Adjuvant
Description: s.c. injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant without active component
Description: s.c. injection
Study: NCT01887405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline auto-injector
Description: Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline auto-injector
Description: Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water
Study: NCT02722408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: 300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
Study: NCT04084535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
Study: NCT01510873

Intervention type: OTHER
Intervention: HRQOL evaluation
Description: Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start.

Intervention type: OTHER
Intervention: HRQOL evaluation
Description: Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start.

Intervention type: OTHER
Intervention: HRQOL evaluation
Description: Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start.
Study: NCT00360958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrafiltration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrafiltration
Study: NCT00427011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
Study: NCT02359006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline will be compared with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be compared with minocycline
Study: NCT00878267

Intervention type: BEHAVIORAL
Intervention: Interview
Description: 3 step process including person to person meeting and questionnaires taking about 30 minutes.